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Myelodysplastic Syndromes
Introduction
Myelodysplastic syndromes (MDS) comprise a heteroge-
neous group of clonal hematopoietic diseases with ineffective
hematopoiesis, peripheral blood cytopenias and a substantial
risk of progression to acute myeloid leukemia. The World
Health Organization classifies MDS according to the percent-
age of blasts in the bone marrow, number and type of hema-
tologic lineage(s) affected, presence of ringed sideroblasts,
and the cytogenetic aberrations in hematopoietic cells, for
example interstitial deletion of the long arm of chromosome
5 [del(5q)], which leads to a well-defined subset of MDS
mostly with a rather favorable prognosis.1 In some MDS cat-
egories a specific cytogenetic aberration, mutation and/or epi-
genetic alteration in the hematopoietic cells explains, at least
partially, the behavior of the MDS.2,3 In fact, the del(5q) sub-
type is associated with more responsiveness to lenalidomide
(LEN, an immunomodulatory agent, IMiD®) in low/interme-
diate-1-risk MDS patients.4,5
In spite of intensive research on the biology of CD34+
hematopoietic stem and progenitor cells (HSPC) in MDS,
cytogenetic and molecular data do not completely clarify how
the progression from low risk/less advanced MDS with dys-
plastic progenitors and apoptosis in the bone marrow to high
risk/advanced MDS with an excess of blasts occurs. While
mutations might lead to the transformation of a HSPC, the
latter cannot survive and expand in the absence of a support-
ive microenvironment.6-8
Recent striking findings indicate a decisive role of the bone
marrow microenvironment in the pathophysiology and dis-
ease progression of MDS;9-12 nevertheless, the heterogeneity
of the disease has generated conflicting results. Mesenchymal
stromal cells (MSC) are a main component of the hematopoi-
etic niche; MSC and their progeny – endosteal osteoprogeni-
tors, perivascular cells, nestin+ cells, CXCL12 abundant retic-
ular cells, among others – regulate the localization, number,
and fate of HSPC.13-15 MSC also possess immunomodulatory
activity and some reports point to a defect in this regard in
MDS.16-17 A recent study by our group also showed that the
properties of MSC from healthy donors can be modulated by
LEN treatment,18 but whether this also applies to MSC
derived from MDS patients is unknown. 
Here we investigated the functionality of MSC and their
modulation by LEN from patients with different disease sub-
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The contribution of the bone marrow microenvironment in myelodysplastic syndrome is controversial. We there-
fore analyzed the functional properties of primary mesenchymal stromal cells from patients with myelodysplastic
syndrome in the presence or absence of lenalidomide. Compared to healthy controls, clonality and growth were
reduced across all disease stages. Furthermore, differentiation defects and particular expression of adhesion and
cell surface molecules (e.g. CD166, CD29, CD146) were detected. Interestingly, the levels of stromal derived factor
1-alpha in patients’ cells culture supernatants were almost 2-fold lower (P<0.01) than those in controls and this
was paralleled by a reduced induction of migration of CD34+ hematopoietic cells. Co-cultures of mesenchymal
stromal cells from patients with CD34+ cells from healthy donors resulted in reduced numbers of cobblestone area-
forming cells and fewer colony-forming units. Exposure of stromal cells from patients and controls to lenalidomide
led to a further reduction of stromal derived factor 1-alpha secretion and cobblestone area formation, respectively.
Moreover, lenalidomide pretreatment of mesenchymal stromal cells from patients with low but not high-risk
myelodysplastic syndrome was able to rescue impaired erythroid and myeloid colony formation of early
hematopoietic progenitors. In conclusion, our analyses support the notion that the stromal microenvironment is
involved in the pathophysiology of myelodysplastic syndrome thus representing a potential target for therapeutic
interventions.
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ABSTRACT
types including MDS associated with single del(5q), and
characterized their clonogenicity and differentiation
potential.
Methods
Human samples
Twenty MDS patients were studied; their characteristics are
detailed in Online Supplementary Table S1. Our control cohort con-
sisted of one male and five female healthy individuals undergoing
orthopedic surgery with a median age of 60 years (range, 56-65).
MSC were obtained as previously described.18 Patients were clas-
sified for the study as “lower risk” with and without del(5q) (LR,
LR-5q ) (<5% bone marrow blasts and IPSS-low/int-1), and as
“higher-risk” (HR) (>5% bone marrow blasts and IPSS-int-2/high).
Magnetically sorted HSPC were obtained from peripheral blood of
healthy individuals after mobilization. Samples were collected
after approval by our Institutional Review Board, and written
informed consent was obtained. A detailed description is available
in the Online Supplementary Material.
Lenalidomide treatment
LEN was kindly provided by Celgene (Munich, Germany) and
prepared using 10% dimethyl-sulfoxide as a vehicle. The experi-
ments were performed with 0.1 μM and 1 μM of the drug.
Characterization of the mesenchymal stromal cells 
Clonality, self-renewal, generation of single cell-derived
colonies (SCD), expression of cell surface and adhesion molecules
with flow cytometry, differentiation potential, proliferation, via-
bility, apoptosis, senescence, and cell cycle were studied. Detailed
information about the experiments is provided in the Online
Supplementary Material.
Co-culture of myelodysplastic syndrome-mesenchymal
stromal cells with hematopoietic stem and progenitor
cells, clonogenicity and apoptosis assay 
The capacity of MSC to support HSPC was tested using a 4-
week cobblestone area-forming (CAF-C) assay and a 14-day
colony-forming unit granulocyte-erythrocyte-
monocyte/macrophage (CFU-GEMM) assay as described in the
Online Supplementary Material. HSPC or the cell line KG1-α were
labeled with carboxyfluorescein-diacetate-succinimidyl-ester
(CFSE) prior to co-culture with MSC for 72 h, or left unlabeled and
co-cultured for 24 h, with or without the addition of 100 nM
recombinant tumor necrosis factor alpha (TNF-α, Peprotech).
Apoptosis and proliferation were studied by annexin-V staining
and CFSE dilution using flow cytometry. 
Cytokine measurement and transwell migration assay 
Supernatant from MSC was obtained after culture with or with-
out LEN and used for enzyme-linked immunoabsorbent assay
(ELISA) determinations of SDF-1α, angiopoietin-1 (ANG1), and
stem cell factor (SCF) levels. Supernatant was also used for a 4-h
transwell migration assay with 1x105 HSPC, as described previ-
ously.18 The CXCR4 antagonist AMD3100 (Sigma) was used at a
concentration of 10 μM.
RNA extraction, complementary DNA synthesis 
and real time polymerase chain reaction 
mRNA extracted with Trizol reagent (Invitrogen) was tran-
scribed into complementary-DNA and used for real time poly-
merase chain reaction (RT-PCR) analysis for fatty acid binding pro-
tein 4 (FABP4), SDF-1α , ANG1, and SCF. Abelson murine
leukemia viral oncogene homolog 1 (ABL-1) was used to normal-
ize values of relative gene expression. Primer sequences are pro-
vided in the Online Supplementary Material.
Statistical analysis
Significance was assessed with the unpaired t-test using
Graphpad Prism software version 5 (GraphPad Software, San
Diego, CA, USA). The results are presented as mean ± SEM from
at least three different donors per group. The level of statistical sig-
nificance was set at P≤0.05. 
Results
Mesenchymal stromal cells from myelodysplastic 
syndrome patients display abnormal characteristics 
Compared to MSC from healthy age-matched controls,
those from MDS patients presented altered morphology
and in some MDS cases appeared disorganized (Figure
1A). They were clonal and able to generate SCD colonies;
however, both LR- and HR-MSC displayed reduced num-
bers of colonies, while all groups presented conserved self-
renewal (Figure 1B,C). The studied cells were positive for
known MSC markers (CD90, CD73, and CD105) and neg-
ative for the hematopoietic markers CD34 and CD45
(Online Supplementary Figure S1). Interestingly, CD105
expression was lower in HR-MSC than in LR-5q-MSC
(P=0.0162) (Online Supplementary Figure S2). MSC derived
by plastic adherence and by SCD plating had altered
potential for osteogenic differentiation compared to those
of healthy donors (LR-5q-MSC 49%, LR-MSC 69%, and
HR-MSC 96%). Cell-specific alkaline phosphatase activity
measurement confirmed this observation (Figure 1D,
Online Supplementary Figure S2). Adipogenic differentiation
potential was also evidenced using oil red staining and
was 9-fold higher in MSC from healthy subjects than in
MSC from LR-5q patients, 37-fold higher than LR-MSC,
and 22-fold higher than HR-MSC. This difference in adi-
pogenic differentiation potential was reflected by the
mRNA expression levels of FABP4 (Figure 1D, Online
Supplementary Figure S2). LEN treatment did not affect any
of the aforementioned characteristics in healthy and
MDS-MSC (data not shown).
Proliferation of myelodysplastic syndrome-mesenchymal
stromal cells is disturbed as a result of increased
senescence
MSC from healthy donors could be expanded from
5x104 seeded cells to 1.42±0.22x105 cells after 14 days of
culture; this number was similar to that reached by LR-5q-
MSC (1.29±0.18x105), and higher than that of LR-MSC
(8.39±0.1.54x104, P<0.01) and HR-MSC (6.13±1.92x104,
P<0.001; Figure 2A, Online Supplementary Figure S3). Pulse
labeling with 5-ethynyl-2’-deoxyuridine for 96 h showed
reduced short-term proliferation while tracking of CFSE
confirmed the impaired growth during the whole culture
period (14 days) (Online Supplementary Figure S3). There
were no differences between groups at any studied time
point for cell viability as measured by trypan blue exclu-
sion (data not shown) and annexin V+ cells (Figure 2B). β-Gal
staining of MSC showed a significantly higher percentage
of senescent MSC from MDS patients (Figure 2C). The
described proliferation defects were compatible with an
increased percentage of G1-arrested cells in LR and HR
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(Online Supplementary Figure S3). LEN treatment did not
improve the proliferation impairment of MDS-MSC (mea-
sured by MTT assay) and had no influence on the percent-
age of apoptotic cells (Online Supplementary Figure S4).
Specific adhesion molecule profiles in myelodysplastic
syndrome groups
The interaction of MSC with HSPC is mediated by
adhesion molecules expressed on their surface; we, there-
MSC in MDS subtypes and effect of lenalidomide
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Figure 1. MSC originated from MDS patients and
healthy donors possess clonality and have different
characteristics. (A) MSC are characterized by
increased frequency of cells with a dysplastic appear-
ance (lower panel, Giemsa staining 10X magnifica-
tion, insets showing a cell in detail) and produce dis-
organized stromal layers (upper panel, 10X magnifi-
cation). (B) MSC are able to generate fibroblastic
colonies across two passages (P, and SubP) in all
studied groups. (C) MSC can produce single cell
derived (SCD) colonies; these colonies retain self-
renewal and clonogenic potential (SubP-SCD). (D)
MSC derived by plastic adherence and by SCD plating
have distinct degrees of osteogenic and adipogenic potential, as seen by van Kossa staining (first 2 rows, 20X magnification) and by oil red
staining (second 2 rows, 20X magnification). Results are expressed as mean ± SEM of independent cases, for (B) numbers were Healthy=6,
LR-5q=6, LR=6 and HR=5; for (C) n=4 for all groups and n=3 for SubP. Significance was set as *P≤0.05; **P≤0.005; ***P≤0.001.
Figure 2. Proliferation of MDS-
MSC is impaired. (A)
Proliferation curves for each
group were determined by
seeding 5x104 cells and meas-
uring cell number at days 2, 4,
6, 8, and 14. (B) Apoptosis of
MSC after 14 days of culture
was determined by annexin V
staining. (C) Senescence of
MSC was demonstrated by β-
galactosidase (β-gal) staining
after 48 h of culture of 1x103
cells per donor. Results are
expressed as mean ± SEM of
independent cases. For (A)
numbers were Healthy=6, LR-
5q=6, LR=6 and HR=5; for (B)
Healthy n=6, LR-5q n=9, LR
n=3 and HR n=3; (C) all groups
n=4. Significance was set as
*/P≤0.05; **/††/‡‡P≤0.005;
***P≤0.001.
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fore, studied molecules relevant to intercellular interac-
tions in hematopoietic homeostasis. Expression (mean flu-
orescence intensity, MFI) of CD146 was significantly high-
er in LR-5q-MSC (P=0.0449) than in MSC from healthy
donors; higher levels of CD166 and CD29 were expressed
in LR-MSC (P=0.0005 and P=0.0115, respectively) com-
pared to healthy controls. The MFI of CD49e in LR-5q-
MSC was higher than in HR-MSC (P=0.003); CD44 and
CD54 were not expressed in healthy donors, LR-MSC or
HR-MSC (MFI<5) while LR-5q-MSC were positive for
these molecules (Online Supplementary Figure S5). LEN
treatment did not modify the expression of adhesion mol-
ecules (data not shown).
Reduced provision of hematopoietic niche cytokines 
by myelodysplastic syndrome-mesenchymal stromal
cells and its modulation by lenalidomide
Cytokines secreted by MSC control the fate and behav-
ior of HSPC; alterations of their levels might result in
defective support of hematopoiesis and contribute to
malignancy. We investigated three important niche
cytokines: SDF-1α, SCF, and ANG-1. The relative mRNA
expression of SCF and SDF-1α was lower in all MDS
groups (albeit only statistically significantly so for SCF:
LR-5q-MSC P=0.015; LR-MSC P=0.005; HR-MSC P=0.16)
while ANG1 expression was only slightly reduced in LR-
MSC and HR-MSC compared to in healthy donors (Figure
R.A. Ferrer et al.
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Figure 3. MSC provision of
hematopoietic niche cytokines
is altered in MDS. (A) RT-PCR
with ABL-1 as reference gene
and RNA extracted from MSC
cultured for 14 days was used
to determine the relative gene
expression of SDF-1α, ANG1
and SCF. (B) ANG-1 concentra-
tion in MSC-supernatant (SN)
was measured with an ELISA.
(C) SDF-1α secretion by MSC
with and without LEN treat-
ment was measured with an
ELISA on MSC-SN after 7 days
of culture (C1) or 7 days cul-
ture + wash + 72 h of further
culture without drug (C2). (D)
The previously shown defect of
SDF-1α secretion was func-
tionally coupled to reduced
migration of CD34+ healthy
cells towards MSC-SN collect-
ed 72 h after washing and cul-
ture without drug; to show
dependence of the effect on
the SDF-1α/CXCR4 axis,
AMD300 (CXCR4 inhibitor)
was used at a concentration of
10 μM. Results are expressed
as mean ± SEM of fold expres-
sion compared to controls
which were set to 1 of inde-
pendent cases. For (A) the
numbers were Healthy=3, LR-
5q=4, LR=4 and HR=4 for
SDF-1 α and n=3 for all groups
for SCF and ANG1; for (B) n=4
for all groups; for (C) the num-
bers were Healthy=6, LR-
5q=6, LR=5 and HR=5 in (C1)
and Healthy=4, LR-5q=4,
LR=3 and HR=4 in (C2); for (D)
n=3 for all groups. ΩIndicates
difference between healthy
and MDS groups without treat-
ment. Significance was set as
*/ΩP≤0.05; **/Ω ΩP≤0.005;
***/Ω Ω ΩP≤0.001.
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3A); LEN treatment did not affect mRNA expression of the
cytokines (data not shown). The concentration of SCF in
MSC-supernatant was below the level of detection in all
groups (data not shown). ANG1 secretion was higher in LR-
5q-MSC than in other MDS groups (P=0.02 versus LR-
MSC, P=0.0002 versus HR-MSC); HR-MSC also presented
with a lower secretion compared to healthy MSC
(P=0.0008) and LR-MSC (P<0.0001) (Figure 3B). We did
not detect changes in ANG1 secretion during LEN treat-
ment (data not shown). SDF-1α levels in supernatant from
MDS-MSC were lower than in healthy donors (healthy
450.8±63.36 pg/μL; LR-5q-MSC 275±30.96 pg/μL; LR-
MSC 264.4±46.15 pg/μL; and HR-MSC 297.1±58.12
pg/μL) (Figure 3C). The two concentrations of LEN used to
treat MSC affected SDF-1α levels by further reducing
them 1.52- and 1.86-fold in healthy donors, 1.68- and
5.83-fold in LR-5q-MSC, 1.37- and 1.81-fold in LR-MSC,
and 1.16- and 1.7-fold in HR-MSC (Figure 3C-1). The
effect of LEN treatment was observed up to 72 h after
removal of the drug (Figure 3C-2). A reduced SDF-1α con-
centration in supernatant resulted in less migration of nor-
mal CD34+ cells when used as chemoattractant and MSC
priming by LEN caused a further reduction of SDF-1α and
migration (Figure 3C,D). The specificity of the investigat-
ed chemokine-receptor interaction was confirmed by
using the CXCR-4 (SDF-1α receptor) antagonist
AMD3100, resulting in equally reduced migration in
experiments with a high concentration of LEN (and the
lowest SDF-1α concentration) and experiments with or
without LEN and antagonist (Figure 3D). 
Reduced support of primitive healthy hematopoietic
stem and progenitor cells by myelodysplastic 
syndrome-mesenchymal stromal cells is modulated
by lenalidomide
HSPC purified from the peripheral blood of healthy
donors were supported to a lesser extent by MDS-MSC,
as shown by a CAF-C assay (healthy versus LR-5q-MSC
P≤0.0001; versus LR-MSC P=0.0026; versus HR-MSC
P≤0.0001), and co-culture of HSPC with HR-MSC led to
significantly reduced numbers of CAF-C when compared
to other MDS subgroups (Figure 4). Priming of MSC with
LEN produced further CAF-C reductions in all groups:
healthy donors, 1.45- and 2.08-fold reductions; LR-5q-
MSC, 2.09- and 6.67-fold reductions; LR-MSC, 1.53- and
1.69-fold reductions, and HR-MSC, 1.79- and 1.95-fold
reductions (Figure 4). 
Myelodysplastic syndrome-mesenchymal stromal cell
support of expanding normal clonogenic hematopoietic
progenitors is defective and influenced by lenalidomide
MSC not only support primitive HPSC but also pro-
vide signals to these cells for fate determination and
expansion of differentiating progeny. We performed CFU
assays with HSPC in the presence of MSC. HSPC co-cul-
tured with healthy donors’ MSC for 14 days resulted in
greater expansion of all types of CFU as compared to
HSPC without co-culture (Figure 5). Compared to HSPC
alone, co-culture with LR-MSC resulted in increased
numbers of granulocytic colonies (CFU-G, 1.45-fold) and
granulocyte-macrophage colonies (CFU-GM, 3.93-fold),
with LR-5q-MSC there was a 1.36-fold increase in CFU-
G and co-culture with HR-MSC generated a modest
increase of macrophage colonies (CFU-M 1.16-fold)
MSC in MDS subtypes and effect of lenalidomide
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Figure 4. Hematopoietic support by MDS-MSC is impaired and affected
by LEN treatment. CAF-C numbers were determined after seeding
1x103 CD34+ healthy cells on MSC layers with or without LEN condition-
ing and co-culture for 28 days. Results are expressed as mean ± SEM
of independent cases. Numbers were Healthy=6, LR-5q=6, LR=5 and
HR=5. ΩIndicates difference between healthy and MDS groups without
treatment. Significance was set as *P≤0.05; **/ΩΩP≤0.005;
***/ΩΩΩP≤0.001.
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Figure 5. Support of expansion of
healthy clonogenic progenitors by
MDS-MSC is defective and modified by
LEN. MSC were seeded on 35 mm
plates and used for co-culture with
1x103 healthy CD34+ cells using semi-
solid media. After 14 days of co-cul-
ture, hematopoietic colony output was
determined under an inverted micro-
scope; the figure shows differences of
colony type and numbers of each
studied group and compares them to
the baseline CFU-GEMM potential of
the HSPC on an assay without stroma
present. Results are expressed as
mean ± SEM of independent cases.
Numbers were HSPC alone n=3,
Healthy n=5, LR-5q n=6, LR n=5 and
HR n=5. Significance was set as *
P≤0.05; **P≤0.005; *** P≤0.001.
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(Figure 5). LEN pre-treatment of MSC led to a further
increase of CFU-GME in the healthy group, a significant
rescue of all types of colonies in the LR-5q-MSC co-cul-
tures, and expansion of BFU-E and CFU-E in LR-MSC,
and an increase of CFU-GM was observed when LEN
pre-treated HR-MSC were used (Online Supplementary
Figure S6).
Myelodysplastic syndrome-mesenchymal stromal cell
contact induces differential apoptotic and proliferative
responses in healthy hematopoietic stem 
and progenitor cells and leukemic blasts
The bone marrow of MDS patients contains a mixture
of healthy and malignant cells. Their proliferation and
apoptosis might be differentially affected by stroma con-
tact and the cytokine microenvironment with TNF-α
being the most important player.19 Proliferation as meas-
ured by CFSE staining of healthy HSPC was increased
when in contact with MDS-MSC, markedly so in LR-MSC
and HR-MSC compared to healthy donors’ stroma, and
was unaffected by the addition of TNF-α or LEN (data not
shown, Figure 6A). In terms of apoptosis of HSPC, stroma
contact without addition of TNF-α did not produce an
effect irrespective of MSC group (data not shown). The
addition of TNF-α led to increased apoptosis of leukemic
cells (increased number of apoptotic cells in the fraction of
cells detached from stroma) which increased by disease
stage (healthy 14.68±2.59%; LR-5q-MSC 21.27±3.56%;
LR-MSC 41.94± 6.8%; HR-MSC 65.36±7.1%) (Figure 6B).
Pretreatment of MSC with LEN did not significantly
increase the sensitivity of HSPC and KG1-α to TNF-α
(Figure 6B and data not shown). 
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Figure 6. MSC from MDS patients
induce different apoptotic and prolif-
erative responses on healthy HSPC
and KG1-α leukemic cells. (A)
Proliferation of CD34+ healthy cells
and KG1-α cells was determined
using CFSE staining and co-culture
with stroma with or without addition
of 100 nM of TNF-α measuring the
dilution of the dye after 72 h by flow
cytometry. The histograms show the
percentage of cells that diluted CFSE
beyond the level at day 0 of represen-
tative examples in the non-adherent
fraction after co-culture with TNF-α
(results were similar in all fractions
regardless of cytokine presence). (B)
Effect on apoptosis after co-culture
with stroma was only evident in KG1-
α cells and in the fraction of cells that
after 24 h were not attached to the
MSC layers; the percentage of annex-
in+ cells is shown for both HSPC and
KG1-α in the non-adherent fraction
(apoptosis was similarly low to that of
cells without co-culture in all fractions
with HSPC and in the adherent frac-
tion of KG1-α). Ω indicates differ-
ences between cells alone with TNF-α
and cells co-cultured with stroma.
Results are expressed as mean ±
SEM of independent cases. For (A)
numbers were Healthy=6, LR-5q=6,
LR=5 and HR=5; for (B) n=3 for HSPC
experiments and n=4 for KG1-α for all
groups. Significance was set as
*/‡/ΩP≤0.05; **/††/ΩΩP≤0.005;
†††/‡‡‡P≤0.001. 
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Discussion
Primary MSC from MDS patients at different stages of
disease have not been systematically characterized so far
and this characterization was, therefore, the goal of our
current study. The biology of MDS subtypes according to
current classification systems is different and we hypoth-
esized that MSC from patients at distinct stages of the dis-
ease might have variable functional properties. The clini-
cal observation that some cases of LR-MDS, including
patients with single del(5q), respond to LEN treatment
was of special interest for our work. We, therefore, tried
to investigate whether this agent modulates MSC from
MDS patients differentially.
Although MSC do not seem to be part of the malignant
clone,20 targeted deletion of parts of the microRNA pro-
cessing machinery in cells of the osteogenic lineage has
been shown to be sufficient to induce clonal hematopoiet-
ic disorders including MDS and leukemia in an animal
model.10 CFU-F assays showed that MDS-MSC were
capable of generating colonies even at very low density
seeding, proving that single cells possess clonality. The
generated colonies had self-renewal and differentiation
potential. Sarugaser et al. demonstrated that seeding 0.2
cells per well isolates SCD clones with similar capacities in
vitro and in vivo.21 To our knowledge, this cloning strategy
has now been applied for the first time in MSC from MDS
patients. Overall, clonality and proliferation of LR- and
HR-MSC was reduced, partially in line with the findings
of Klaus et al. as well as others. However, these authors
did not study cases in relation to any specific disease
group.22,23 In other studies it was shown that MDS-MSC
have reduced proliferative capacity although the investiga-
tors succeeded in expanding them in vitro.22,24,25 Two studies
by Aanei et al. demonstrated again that MDS-MSC pres-
ent intrinsic growth deficiencies that are related to focal
adhesion protein abnormalities; the MSC from patients
with refractory cytopenia (mostly LR-MDS patients) had
reduced proliferation capacity while cells from patients
with an excess of blasts (HR-MDS patients) had increased
proliferation.26,27 This differs from our observations and
may be explained by differences in the patients’ character-
istics, cell sorting strategy, and culture conditions.
MDS-MSC were positive (>90%) in all cases for CD73,
CD90 and CD105; these markers are homogeneously
expressed on MSC and useful for robust in vitro assays.28,29
However the MSC derived from patients with HR-MDS
had a significantly reduced expression of CD105.
Campioni et al. demonstrated that reduced CD105 and
CD90 expression in MSC from patients with hematologic
malignancies is related to increased angiogenesis, a feature
of HR-MDS.30 Our findings are in agreement with those of
Lopez-Villar but these investigators did not report on dis-
tinct MDS subgroups.24
MDS-MSC showed various degrees of osteogenic differ-
entiation, while the adipogenic potential was significantly
lower in all MDS groups than in healthy controls.
Mellibovsky et al. showed that MDS patients have a typi-
cal adynamic bone with decreased mineral deposition31
and a recent study by Raaijmakers demonstrated how
Dicer1 deletion in mice osteoprogenitors leads to bone
dysfunction and development of MDS that progresses to
AML.10 Varga et al.25 previously described similar defective
adipogenic differentiation in MDS-MSC. Defects of differ-
entiation potential of MSC might have a role in MDS
pathophysiology. 
The support that MDS-MSC provided HSPC was
impaired. CAF-C (representing primitive HSPC) numbers
were reduced in co-cultures with all MDS groups as was
the short-term expansion of committed CD34+ progeni-
tors (CFU-GEMM). Previous reports state that MDS-MSC
are able to sustain the growth of healthy HSPC, but the
investigators did not provide a detailed analysis of differ-
ent clonogenic precursor subsets according to MDS
groups.20,23,32,33 Varga et al. showed that MDS-MSC provide
reduced hematopoietic support.25 Regarding the influence
of MSC on CD34+ cell differentiation, we provide the first
evidence of a specific deficiency of MDS-MSC correlating
with disease category. It remains to be investigated which
pathways are involved in the dysregulated induction of
differentiation.
SDF-1α secretion by MDS-MSC was reduced and func-
tionally coupled with lower induction of migration of nor-
mal CD34+ cells. Expression of the gene for SDF-1α has
been reported to be decreased in MDS-MSC.24
Interestingly, a leukemia mouse model showed that
leukemic infiltration of the bone marrow is accompanied
by a reduction of SDF-1α activity.34 Another mouse model
suggests that SDF-1α knock-down in stromal cells results
in reduction of long-term HSPC and an increased progen-
itor pool;35 this might be reflected in the case of our
patients’ cells by reduced CAF-C numbers. An imbalance
of SDF-1α in MDS-MSC might be involved in the prolif-
eration defects of MSC and the increased senescence of
these cells: decreased SDF-1α gene expression in MSC or
disturbances in its intracellular pathways leads to impaired
cell survival, cytoskeletal disorganization and defective
differentiation.36,37
SCF gene expression was down-regulated in MDS-
MSC. It has been reported that SCF levels are elevated in
bone marrow plasma of MDS patients, but with no statis-
tical significance and without identification of the specific
source of the cytokine.38,39 It has been demonstrated that
loss of cells expressing SCF in the perivascular niche leads
to a reduction of HSPC with long-term repopulating capa-
bility.40 ANG1 expression was also reduced in HR-MSC.
This cytokine is responsible for the maintenance of HSPC
quiescence,15 and its lower level in this MDS subset might
also explain the reduced support of HSPC.
Adhesion molecules play a pivotal role in MSC-HSPC
communication. CD146 (melanoma cell adhesion mole-
cule, MCAM) was up-regulated in LR-5q-MSC.
Interestingly, we have recently shown that CD146 expres-
sion in MSC participates in HSPC support.41 It could be
speculated that a higher expression of CD146 in this group
represents a compensatory mechanism in response to
stress hematopoiesis. CD166 expression was up-regulated
in LR-MSC and HR-MSC. This is the first report on
CD166 expression in MDS-MSC. CD166 (activated leuko-
cyte cell adhesion molecule, ALCAM) has been related to
increased aggressiveness of solid tumors,42 but its signifi-
cance in the context of MDS requires further studies.
CD29 (integrin β-1) MFI was also elevated in LR-MSC and
HR-MSC; MSC overexpression of this molecule is related
to increased proliferation of HSPC and loss of primitive-
ness.43 Only LR-5q-MSC expressed CD44 (cell surface gly-
coprotein) and CD54 (intercellular adhesion molecule 1)
and had the highest expression of CD49e (integrin α-5).
Low expression of CD44 and CD49e is related to low pro-
liferation on MDS-MSC,26 as is in our case with LR-MSC
MSC in MDS subtypes and effect of lenalidomide
haematologica | 2013; 98(11) 1683
and HR-MSC. Moreover, CD44 expression has been
shown to be negative in normal MSC.44
Increased apoptosis of hematopoietic progenitors is a
prominent feature of MDS and is mainly mediated by
TNF-α; in this regard It has been shown that healthy and
MDS-MSC are able to induce apoptosis in KG1-α cells in
the presence of TNF-α, while normal CD34+ cells are not
affected by this combination.45 Nevertheless, the apoptosis
and proliferation profiles of healthy HSPC and KG1-α cells
in contact with MSC from different MDS subsets have
never been studied. We showed that both healthy and
KG1-α cells exhibit excessive proliferation with stroma
contact, especially with LR-MSC and HR-MSC, regardless
of the presence of the cytokine, while stroma contact and
TNF-α only affect leukemic cells increasing their rate of
apoptosis, markedly so in the LR-MSC and HR-MSC
groups. The increased proliferation of HSPC in short-term
cultures might explain our findings of impaired support of
CAF-C during longer periods of culture. The suspected
stromal dysfunction might in part also explain the para-
doxical finding of hypercellularity in patients´ bone mar-
row despite peripheral pancytopenia, and could con-
tribute to oncogenesis by inducing genetic instability in
HSPC.7,19,35
LEN has been successfully used to treat MDS patients
with IPSS low to intermediate risk, and to a greater extent
in those presenting with del(5q). We show that this thera-
peutic agent does not affect the clonality, vitality, growth
and differentiation potential of MDS-MSC and MSC from
age-matched healthy individuals. We and others have
reported the absence of toxicity of this drug on healthy
MSC or other non-malignant cells.46 The influence of LEN
on the expression of cell surface markers was also investi-
gated; pharmacological concentrations of the drug did not
affect the phenotype of MSC. Regarding the differentia-
tion potential of MSC, Munemasa et al. tested LEN and
other IMiD® on MSC osteogenic potential and found no
increase or impairment when using the drug.47
LEN incubation with MSC further decreased SDF-1α
secretion in all groups (significantly in LR-5q-MSC and
LR-MSC), and this could be translated functionally into
reduced CAF-C numbers. This effect was described in
healthy MSC by our group.18 It might contribute to the
cytopenia found in patients treated with LEN but at the
same time it could be beneficial by increasing egress of
malignant dormant cells from the niches and increasing
their sensitivity to cytotoxicity of the drug;48 in a murine
model of acute promyelocytic leukemia, blocking the
SDF-1α receptor resulted in sensitization of blasts to
cytarabine and prolonged survival of the mice.49
Interestingly, LEN administration before the expansion of
clonogenic CD34+ cells generated an increased number of
erythropoietic and granulocytic colonies in the healthy
group, a global rescue of CFU output in LR-5q-MSC co-
culture, and an improvement of CFU-E and BFU-E in
CD34 cells cultured on LR-MSC. Anemia is reversed in a
high percentage of patients treated with LEN, and transfu-
sion independence is reached; Ximeri et al. found that after
24 weeks of LEN administration, bone marrow from MDS
patients contained an increased proportion of erythroid
progenitors and the clonogenic potential of myeloid
colonies was increased.50 Since the intercellular crosstalk
and soluble factors responsible for the support of CAF-C
and CFU-GEMM are different, the influence of LEN on
MSC support for each population may be diverse.
In conclusion, our work suggests that MSC from
patients with MDS are functionally different from those of
healthy donors, and that MDS subcategories are each
characterized by specific biological properties. In addition,
the expression of adhesion molecules and chemokines by
MSC from MDS patients seem to be altered leading to a
defect in the migratory capacity and support of HSPC.
LEN was able to modulate important functions of MSC.
These findings call for further investigations to clarify
whether the functional defects in MSC have a definitive
role in the pathogenesis of MDS and, if so, whether this
might open new alternatives for therapeutic interventions.
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